JTE-013|cas:383150-41-2|西域试剂

JTE-013,99.57%

产品编号：Bellancom-100675| CAS NO：383150-41-2| 分子式：C₁₇H₁₉Cl₂N₇O| 分子量：408.29

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100675	￥800.00	杭州北京（现货）
Bellancom-100675	￥1200.00	杭州北京（现货）
Bellancom-100675	￥4500.00	杭州北京（现货）
Bellancom-100675	￥7650.00	杭州北京（现货）
Bellancom-100675	￥10710.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

JTE-013

产品介绍

JTE-013 是一种有效且选择性的 S1P₂ (鞘氨醇1-磷酸2) 拮抗剂。JTE-013 抑制放射性标记的 S1P 与人和大鼠 S1P₂ 的特异性结合，IC₅₀ 分别为 17 nM 和 22 nM。

生物活性

JTE-013 is a potent and specific S1P₂ (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P₂ with IC₅₀s of 17 nM and 22 nM, respectively.

体外研究

JTE-013 (50-200 μM; 1-3 days) reduced cell viability.
JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.
JTE-013 displays 4.2% inhibition of S1P₃ and does not antagonize S1P₁ at concentrations up to 10 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	SK-N-AS cells
Concentration:	50, 100, 150, 200 μM
Incubation Time:	1-3 days
Result:	Reduced cell viability.

Western Blot Analysis

Cell Line:	SK-N-AS cells
Concentration:	10, 100, 1000 nM
Incubation Time:	30 mins
Result:	Reversed S1P-induced Akt inhibition and inhibited S1P-induced ERK activation.

体内研究
(In Vivo)

JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female athymic NCr-nu/nu nude mice
Dosage:	30 mg/kg
Administration:	Gavage; daily for 14 consecutive days
Result:	Reduced tumor size and tumor weight.

体内研究

JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female athymic NCr-nu/nu nude mice
Dosage:	30 mg/kg
Administration:	Gavage; daily for 14 consecutive days
Result:	Reduced tumor size and tumor weight.

体内研究

JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female athymic NCr-nu/nu nude mice
Dosage:	30 mg/kg
Administration:	Gavage; daily for 14 consecutive days
Result:	Reduced tumor size and tumor weight.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (244.92 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4492 mL	12.2462 mL	24.4924 mL
5 mM	0.4898 mL	2.4492 mL	4.8985 mL
10 mM	0.2449 mL	1.2246 mL	2.4492 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 0.83 mg/mL (2.03 mM); Clear solution

此方案可获得 ≥ 0.83 mg/mL (2.03 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.83 mg/mL (2.03 mM); Clear solution

此方案可获得 ≥ 0.83 mg/mL (2.03 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。